Lexaria's DehydraTECH Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
TL;DR
Lexaria's DehydraTECH technology delivers semaglutide more effectively to the brain than Rybelsus, potentially offering superior safety and efficacy advantages in GLP-1 drug markets.
Lexaria's DehydraTECH processing enhances brain biodistribution of semaglutide through improved delivery across the blood-brain barrier, as evidenced by fluorescent imaging in rodent studies.
Enhanced brain delivery of GLP-1 drugs could reduce side effects like nausea while improving weight management, making treatments safer and more effective for patients worldwide.
Lexaria's technology shows semaglutide reaching key brain regions at higher levels than conventional formulations, potentially explaining improved drug performance in human trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has reported successful results from a preclinical study showing its DehydraTECH technology enhances brain biodistribution of semaglutide, a GLP-1 drug used for diabetes and weight management. The study found that DehydraTECH-processed semaglutide achieved higher brain concentrations than conventional formulations, with the 5mg DehydraTECH composition outperforming the 15mg Rybelsus equivalent in brain fluorescent signal intensity.
The research involved fluorescently tagged semaglutide administered to Sprague Dawley rats, with detailed imaging revealing enhanced distribution in key brain regions including the brainstem, hypothalamus, and circumventricular organs. These areas are critical for semaglutide's mechanism of action in regulating appetite and energy expenditure. John Docherty, Lexaria President and CSO, noted that previous studies with other DehydraTECH-processed compounds have shown similar brain enhancement patterns correlating with improved safety and efficacy.
Enhanced brain biodistribution of GLP-1 drugs is particularly significant because these medications increasingly depend on brain neurochemistry for their effects. Semaglutide works through direct and indirect activation of GLP-1 receptors in multiple brain nuclei, influencing neuronal pathways involved in food intake, reward, and energy expenditure. Improved brain delivery could potentially reduce common side effects like nausea while enhancing therapeutic benefits.
The study findings suggest that DehydraTECH technology, which can be explored further at https://www.lexariabioscience.com, may enable unique delivery enhancements that support improved pharmacodynamic performance. The technology's ability to improve drug absorption and cross the blood-brain barrier has been demonstrated in previous research, including human pilot studies GLP-1-H24-1 and GLP-1-H24-2 referenced in the company's research.
This development matters because it addresses significant limitations in current GLP-1 therapies, particularly regarding side effects and optimal dosing. With the growing global market for diabetes and obesity treatments, technologies that improve drug delivery could lead to more effective medications with better patient compliance. The findings support additional research and potential industry partnerships aimed at developing safer, more effective GLP-1 drugs that maximize therapeutic benefits while minimizing adverse effects.
Curated from NewMediaWire
